Rosacea - Pipeline Review, H1 2015

Published: Apr, 2015 | Pages: 94 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Rosacea - Pipeline Review, H1 2015

Summary 

Global Markets Direct's, 'Rosacea - Pipeline Review, H1 2015', provides an overview of the Rosacea's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Rosacea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rosacea and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Rosacea
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Rosacea and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Rosacea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Rosacea pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason To Buy 

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Rosacea
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Rosacea pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Rosacea Overview 8
Therapeutics Development 9
Pipeline Products for Rosacea - Overview 9
Pipeline Products for Rosacea - Comparative Analysis 10
Rosacea - Therapeutics under Development by Companies 11
Rosacea - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Rosacea - Products under Development by Companies 15
Rosacea - Companies Involved in Therapeutics Development 17
Allergan, Inc. 17
Amorepacific Corporation 18
Celgene Corporation 19
Celtaxsys, Inc. 20
Cutanea Life Sciences 21
Delenex Therapeutics AG 22
Dermira Inc. 23
Foamix Pharmaceuticals Ltd. 24
Hovione FarmaCiencia SA 25
Kasiak Research Pvt. Ltd. 26
Merz Pharma GmbH & Co. KgaA 27
Promius Pharma, LLC 28
RestorGenex Corporation 29
TWi Pharmaceuticals, Inc. 30
Valeant Pharmaceuticals International, Inc. 31
Rosacea - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Target 33
Assessment by Mechanism of Action 35
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
AC-701 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
ACUD-1 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
apremilast - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
CTX-4430 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
DLX-1008 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
DRM-02 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
GM-1111 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
incobotulinumtoxin A - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
minocycline - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
minocycline Gel - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
omiganan pentahydrochloride - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
oxymetazoline hydrochloride - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
P-529 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
PAC-14028 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
PDI-320 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Refaglo - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
SIG-990 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Small Molecules for Cancer, Rosacea and Psoriasis - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
tetracycline MR - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Rosacea - Recent Pipeline Updates 69
Rosacea - Dormant Projects 84
Rosacea - Discontinued Products 86
Rosacea - Product Development Milestones 87
Featured News & Press Releases 87
Apr 17, 2014: Treatment for Facial Redness Associated With Rosacea Now Available in the UK 87
Feb 26, 2014: mirvaso the first and only treatment targeting the facial redness of rosacea approved by the european commission 87
Jan 29, 2014: Galderma Announces the Publication of Positive Results of the Long-Term Study of Mirvaso Gel for Treatment of Persistent Erythema of Rosacea 88
Dec 20, 2013: Galderma Receives CHMP Positive Opinion For Mirvaso 89
Sep 27, 2013: Galderma Announces Availability of Mirvaso (brimonidine) Topical Gel, 0.33% 90
Aug 26, 2013: Galderma Receives FDA Approval of Mirvaso 90
Jul 08, 2013: Signum Dermalogix Investigational New Drug Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea 91
Mar 16, 2012: Galderma Completes Phase III Trials Of Investigational Drug Targeting Facial Erythema Of Rosacea 91
Oct 20, 2011: Galderma Announces Positive Phase IIb Results For Investigational Compound Targeting Redness Of Rosacea 92
Aug 15, 2011: Argyle Therapeutics Receives Phase II SBIR Grant To Develop SIG990 92
Appendix 93
Methodology 93
Coverage 93
Secondary Research 93
Primary Research 93
Expert Panel Validation 93
Contact Us 93
Disclaimer 94

List of Tables

Number of Products under Development for Rosacea, H1 2015 9
Number of Products under Development for Rosacea - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Comparative Analysis by Late Stage Development, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Products under Development by Companies, H1 2015 (Contd..1) 16
Rosacea - Pipeline by Allergan, Inc., H1 2015 17
Rosacea - Pipeline by Amorepacific Corporation, H1 2015 18
Rosacea - Pipeline by Celgene Corporation, H1 2015 19
Rosacea - Pipeline by Celtaxsys, Inc., H1 2015 20
Rosacea - Pipeline by Cutanea Life Sciences, H1 2015 21
Rosacea - Pipeline by Delenex Therapeutics AG, H1 2015 22
Rosacea - Pipeline by Dermira Inc., H1 2015 23
Rosacea - Pipeline by Foamix Pharmaceuticals Ltd., H1 2015 24
Rosacea - Pipeline by Hovione FarmaCiencia SA, H1 2015 25
Rosacea - Pipeline by Kasiak Research Pvt. Ltd., H1 2015 26
Rosacea - Pipeline by Merz Pharma GmbH & Co. KgaA, H1 2015 27
Rosacea - Pipeline by Promius Pharma, LLC, H1 2015 28
Rosacea - Pipeline by RestorGenex Corporation, H1 2015 29
Rosacea - Pipeline by TWi Pharmaceuticals, Inc., H1 2015 30
Rosacea - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2015 31
Assessment by Monotherapy Products, H1 2015 32
Number of Products by Stage and Target, H1 2015 34
Number of Products by Stage and Mechanism of Action, H1 2015 36
Number of Products by Stage and Route of Administration, H1 2015 38
Number of Products by Stage and Molecule Type, H1 2015 40
Rosacea Therapeutics - Recent Pipeline Updates, H1 2015 69
Rosacea - Dormant Projects, H1 2015 84
Rosacea - Dormant Projects (Contd..1), H1 2015 85
Rosacea - Discontinued Products, H1 2015 86